Long-term tenofovir dipivoxil treatment can make HBV DNA negative
A study in the journal Hepatology showed HBV DNA-negative HBV patients with high viral loads of chronic hepatitis B treated with long-term tenofovir disoproxil fumarate.
The company is located in:
Tenofovir disoproxil fumarate (TDF) is a precursor ester of tenofovir, a nucleotide reverse transcriptase inhibitor that inhibits hepatitis B virus Replication, so that the serum and liver tissue within the reduced viral load in the body can show a strong anti-hepatitis B virus (HBV) activity.
Researchers from the United States assessed tenofovir disoproxil fumarate (TDF) at 240 weeks in patients with chronic hepatitis B (CHB) at baseline high viral load (HVL, defined as hepatitis B virus DNA ≥ 9 log10 copies / mL) ) Antiviral response after treatment.
Study enrolled 641 patients with HBeAg-negative and HBeAg-positive (129 patients with high viral load) who received 300 mg of 300 mg fumarate tenofovir dipivoxil (HVL n = 82) or 10 mg of Adefovir dipivoxil (ADV) (HVL n = 47), followed by an additional 192 weeks of open-label tenofovir disoproxil treatment. Emtricitabine (FTC) may optionally be added to patients with HBV DNA ≥ 400 copies / mL or after 72 weeks.
The results showed that at week 240, 98.3% of high viral load and 99.2% of non-high viral load patients achieved HBV DNA <400 copies / mL after treatment. Both groups had similar baseline and tissue regression rates at 240 weeks. Patients with high viral load and non-high viral load usually take longer to reach HBV DNA <400 copies / mL but at 96 weeks the percentages of patients with HBV DNA <400 copies / mL are similar in both groups. In patients with high viral load, those initially receiving tenofovir disoproxil fumarate had shorter duration of HBV DNA <400 copies / mL compared to adefovir dipivoxil. Patients with high baseline viral load at baseline had no sustained viremia or amino acid substitutions associated with tenofovir dipivoxil-resistant fumarate at week 240.